HanAll Biopharma

News

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.